Stockscreener 앱 받기
122.06
1.02%
0.5056
Insmed Inc 주식(INSM)의 최신 뉴스
2 New Jersey companies named top places to work for 2026. Here's where - Asbury Park Press
Goldman Sachs initiates Insmed stock coverage with buy rating, $188 target - Investing.com
Insmed Incorporated (INSM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance Australia
Insmed Incorporated (INSM) latest stock news and headlines - Yahoo Finance UK
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - TradingView
Insmed stock price target maintained at $195 by Mizuho on FDA review - Investing.com Canada
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Did FDA Priority Review of ARIKAYCE ENCORE Data Just Shift Insmed's (INSM) Investment Narrative? - finance.yahoo.com
FDA priority review for Insmed's Arikayce sNDA - The Pharma Letter
Why is Insmed stock climbing today? By Investing.com - Investing.com Canada
Insmed stock rises on FDA priority review for Arikayce By Investing.com - Investing.com Canada
FDA Grants Priority Review To Insmed's SNDA For Arikayce For Treatment Of Mac Lung Disease With PDUFA Target Action Date Set For January 28, 2027 - TradingView
Insmed receives FDA priority review for ARIKAYCE - grafa.com
FDA grants priority review for Insmed’s ARIKAYCE lung disease drug By Investing.com - Investing.com Canada
INSM Looks 44.7% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
FDA grants Priority Review to Insmed's ARIKAYCE for full approval in treating MAC lung disease - Pluang
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 - Insmed Incorporated Investor Relations
Insmed Incorporated (INSM) Gets FDA Priority Review; PDUFA Jan 28, 2027 - TradingView
Insmed stock slips after strong earnings surprise and rich valuation debate - AD HOC NEWS
Insmed Stock Price Forecast. Should You Buy INSM? - StockInvest.us
Insmed Inc (INSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Is Insmed (INSM) Fully Priced After Its 296% Revenue Surge? - webull.com
The Fund Exited Insmed (INSM) After the Investment Thesis Played Out - Yahoo Finance
Insmed Expands Community Impact During Fifth Annual Global Day of Good - PR Newswire
1INSM.MI Interactive Stock Chart | INSMED INC Stock - finance.yahoo.com
INSMED Inc Director Brennan David R Sells 25,000 Shares at $124 Each on September 9, 2026 - Kalkine Media
Insmed(INSM.US) Director Sells US$3.1 Million in Common Stock - Moomoo
Insmed Director Sold Shares Worth Over $3.1M - TradingView
Insmed (INSM) director sells 25,000 shares in open-market deal - Stock Titan
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now? - Zacks Investment Research
Insmed (NASDAQ: INSM) director lines up 25,000-share sale - Stock Titan
Exiting Insmed (INSM) Following Disappointing Key Drug Uptake - Yahoo Finance
Can Insmed (INSM) Still Look Reasonable After Raised Sales Guidance? - webull.com
Insmed Incorporated at Cantor Global Healthcare Conference Transcript - GuruFocus
Insmed at Cantor conference: higher sales outlook lifts growth case By Investing.com - Investing.com Australia
Why Insmed (INSM) Stock Is Up Today - Quiver Quantitative
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
Insmed rated Strong Buy with 39% upside on robu... - Pluang
Here's How Much $100 Invested In Insmed 5 Years Ago Would Be Worth Today - Benzinga
Insmed to Present Data across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 - marketscreener.com
Insmed Grants Inducement Awards to 128 New Employees - Intellectia AI
128 new employees receive stock awards from Insmed - Stock Titan
INSM Looks 38.8% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Insmed presents new respiratory drug data at ER... - Pluang
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 - PR Newswire
The top 12 companies hiring in biopharma now - BioSpace
Insmed director Sharoky sells $637,650 of Insmed stock By Investing.com - Investing.com Nigeria
Insmed director Sharoky sells $637,650 of Insmed stock - Investing.com
Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges? - Yahoo Finance
Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business - Yahoo Finance
Insmed Incorporated (INSM): Investor Outlook on a Biotech Pioneer with 68.87% Potential Upside - DirectorsTalk Interviews
If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Insmed (INSM) Q1 2025 Earnings: Results, Market Reaction & History - 24/7 Wall St.
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now? - TradingView
Insmed will speak at two New York healthcare conferences in September - Stock Titan
Insmed director Melvin Sharoky sells $637,650 in shares - investing.com
Mizuho raises Insmed stock price target to $195 on Japan approval - investing.com
0.51%
0.77%
자본화:
|
볼륨(24시간):